Ayala Pharmaceuticals Inc (ADXS)

[fbg0316]

That's an optimistic interpretation for the request for the 30m additional shares. I could see your theory as possible, although past actions would indicate simply another dilution at an unfavorable price. One positive point to add to the shareholder friendly outcome is that the NEO start is on hold because the company said it is amending the Amgen deal related to manufacturing. I could see the delay also related to expanding the deal to another indication such as HOT or AXAL.